- Sessions to address scientific, regulatory, commercial, and market access path for MOGENRY® (sonpiretigene isteparvovec; MCO-010), a one-time, in-office, mutation-agnostic, optogenetic gene therapy currently under FDA and PMDA review
- Co-Founder, CEO Sulagna Bhattacharya to join Keynote Panel on navigating the cell and gene therapy landscape and driving market success; Co-Founder, President Samarendra Mohanty to join Keynote Panel on evolution and future outlook for investment in advanced therapies; and present on disease-agnostic gene therapy for neurodegenerative conditions
- EVP, Value & Access Ramesh Arjunji to present on building early evidence to support access and pricing for rare diseases and joining panel on expanding access to cell and gene therapies; Ananta Ayyagari, Sr. Director-Regulatory, to present on Navigating Global Regulatory Filings
ダラス, Oct. 30, 2026 — ナノスコープ・セラピューティクス, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that members of its leadership team will participate in Advanced Therapies USA 2026, taking place November 4–5, 2026, at the Hynes Convention Center in Boston, Massachusetts. Advanced Therapies USA convenes cell and gene therapy developers, manufacturers, investors, and commercial leaders to address the challenges of bringing advanced therapies from the clinic to patients.
プレゼンテーションの詳細:
セッション: Navigating the Cell and Gene Therapy Landscape: Opportunities & Challenges for Driving Market Success
形式: Keynote Panel Discussion
Moderator: Miguel Forte, CEO, Kiji Therapeutics, and President, ISCT
パネリスト: Sulagna Bhattacharya, MBA, Co-Founder and Chief Executive Officer
日時: Wednesday, November 4, 2026, 9:45 AM ET
位置: Keynote/Theatre 1
セッション: Disease-Agnostic Gene Therapy for Neurodegenerative Conditions
形式: プレゼンテーション
追跡: Gene Therapy (Track 4)
プレゼンター: Samarendra Mohanty, PhD, Co-Founder, President and Chief Scientific Officer
日時: Wednesday, November 4, 2026, 11:30 AM ET
位置: Hall D, Level 2
セッション: Starting Early to Develop Evidence to Support Access & Pricing for Rare Diseases
形式: プレゼンテーション
追跡: Evidence, Pricing & Access (Track 8)
プレゼンター: Ramesh Arjunji, PhD, Executive Vice President, Value & Access
日時: Wednesday, November 4, 2026, 1:55 PM ET
位置: Room 209
セッション: Overcoming Barriers and Expanding Access to Cell and Gene Therapies
形式: パネル・ディスカッション
追跡: Evidence, Pricing & Access (Track 8)
Moderator: Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, FDA
パネリスト: Ramesh Arjunji, Executive Vice President, Value & Access
日時: Wednesday, November 4, 2026, 5:10 PM ET
位置: Room 209
セッション: Where’s the Money? Evolution And Future Outlook for Investment in Advanced Therapies
形式: Keynote Panel Discussion
Moderator: Sven Kili, Partner, Saisei Ventures
パネリスト: Samarendra Mohanty, PhD, Co-Founder and President
日時: Thursday, November 5, 2026, 9:35 AM ET
位置: Keynote/Theatre 1
セッション: Navigating Global Regulatory Filings
形式: プレゼンテーション
Speaker: Ananta Ayyagari, PhD, Sr. Director of Regulatory
日時: Thursday, November 5, 2026, 4:20 PM ET
位置: Room 209
Members of the Nanoscope leadership team will be available to meet with potential partners, investors, and industry stakeholders throughout the conference.
About MOGENRY (sonpiretigene isteparvovec; MCO-010)
Nanoscope’s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope’s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope’s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows. MOGENRY is under review by the FDA for the treatment of RP with severe vision loss and under priority review by the PMDA and MHLW for the treatment of IRDs in Japan.
ナノスコープ・セラピューティクスについて
ナノスコープ・セラピューティクスは、網膜変性疾患により失明した数百万人の患者のために、疾患の種類を問わず視力を回復させる光遺伝学的治療法を開発しています。網膜色素変性症(RP)を対象とした多施設共同無作為化二重盲検プラセボ対照臨床試験であるRESTORE第2b/3相試験で良好な結果が得られたことを受け、NCT04945772), the FDA has accepted and filed the Company’s BLA for MOGENRY, and the PMDA has accepted for priority review the Company’s NDA for MOGENRY for the treatment of IRDs in Japan. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA). Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn.
接触:
ナノスコープ・セラピューティクス社
+1 (817) 857-1186
PR@nanostherapeutics.com
出典 ナノスコープ・セラピューティクス